The results showed that the abnormally expressed lncRNA could affect the sensitivity of cytarabine, docetaxel, and paclitaxel, and TMB (tumor mutational burden) was significantly different in high- and low-expression groups of CASC9 and HCG22, as shown in Figures 10 and 11. The gene discussed is CASC9; the disease is neoplasm.